Home › Interpace Diagnostics Faces Nasdaq Delisting

Interpace Diagnostics Faces Nasdaq Delisting

Nov 30, 2016

NEW YORK (GenomeWeb) – Interpace Diagnostics' stock faces delisting from the Nasdaq due to the company's failure to maintain a minimum of $2.5 million in stockholders' equity, according to a document filed yesterday with the US Securities and Exchange Commission. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb
21
Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

What's Popular?

In Molecular Diagnostics

  1. Liquid Biopsy Panel Expansion Enables Admera Health to Add Immunotherapy Prediction

    Premium

  2. Medicare Covers Adaptive Biotechnologies' ClonoSeq Assay

  3. Curetis Subsidiary Ares Ramping Up NGS Antibiotic Resistance Testing Business

    Premium

  4. Minimal Residual Disease Sequencing Poised to Grow Following Lag in Adoption

    Premium

  5. BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.